Rechercher des projets européens

Tumour Heterogeneity and Somatic Evolution of Unstable cancer genomes (THESEUS)
Date du début: 1 juin 2014, Date de fin: 31 mai 2019 PROJET  TERMINÉ 

SummaryThe majority of metastastic solid tumours remain incurable. In-depth analysis of tumour genomes is revealing evidence for branched evolution and cancer subclonal spatial and temporal intratumour heterogeneity (ITH). Drivers of ITH such as chromosomal instability (CIN) are associated with drug resistance and poor clinical outcome. However, despite increasing knowledge of tumour diversity, there is limited insight into the mechanisms driving genomic instability and ITH or the processes that shape cancer genome evolution over time and space. Many animal tumour models fail to recapitulate patterns of genomic instability witnessed in human tumours, limiting insight into the forces that shape tumour evolution in vivo. We have found evidence for parallel subclonal evolution, resulting in the same gene or signal transduction pathway being subject to distinct inactivating or activating somatic events in different regions of the same tumour (Gerlinger NEJM 2012). These data suggest that in-depth analysis of tumour evolution may help define routes through which tumours must progress, offering opportunities for novel therapeutic approaches. We will develop new animal models of ITH, by developing knock-out strains for two suppressors of replication stress and CIN, recently identified in our laboratory (Burrell Nature 2013). These models will be used to study cancer evolution in order to decipher the impact of selection pressures, such as DNA damaging agents and cancer cytotoxics, on genomic complexity and diversity in emergent resistant subclones. In addition, through combined cancer informatics and functional genomics approaches we aim to identify novel mechanisms driving tumour heterogeneity and biological processes that permit the propagation of heterogeneous cells using novel transposon based approaches. Developments in this proposal may lead to new insight into the two forces underpinning cancer evolution and therapeutic failure, diversity and selection



2 Participants partenaires